Medical Oncology

, Volume 29, Issue 3, pp 1707–1710

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

Authors

    • Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of Miami
  • Soley Bayraktar
    • Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of Miami
  • Peter Hosein
    • Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of Miami
  • Emerson Chen
    • University of Miami Miller School of Medicine
  • Leonidas G. Koniaris
    • Division of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer CenterUniversity of Miami
  • Caio Max S. Rocha-Lima
    • Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of Miami
  • Alberto J. Montero
    • Division of Hematology/Oncology, Department of Medicine, Sylvester Comprehensive Cancer CenterUniversity of Miami
Short Communication

DOI: 10.1007/s12032-011-0093-8

Cite this article as:
Bayraktar, U.D., Bayraktar, S., Hosein, P. et al. Med Oncol (2012) 29: 1707. doi:10.1007/s12032-011-0093-8

Abstract

Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2–3 cycles of preoperative docetaxel 75 mg/m2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m2 (continuous infusion) on days 1–5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3–4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7–29.5) and 18.8 months (95% CI: 9.9–27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

Keywords

Gastric cancerEsophageal cancerPreoperative chemotherapyDocetaxel

Copyright information

© Springer Science+Business Media, LLC 2011